Core Insights - PacBio has partnered with Basecamp Research to utilize its HiFi sequencing technology on the Revio system for the Trillion Gene Atlas initiative, aiming to generate a vast metagenomic dataset from approximately 100,000 samples across 31 countries and 5 continents [1][4] Group 1: Collaboration and Project Scope - The collaboration with Basecamp Research is expected to create the largest and most diverse high-fidelity metagenomic dataset to date, enhancing the understanding of evolutionary genetic diversity [1][4] - The Trillion Gene Atlas aims to expand known evolutionary genetic diversity by 100-fold, leveraging PacBio's sequencing technology to capture essential genomic structures [4][6] Group 2: Technology and Methodology - PacBio's HiFi sequencing combines high accuracy with long reads, enabling the resolution of complex genomes and microbial communities, which is crucial for metagenomic studies [3][6] - The SPRQ-Nx chemistry enhances sequencing efficiency and cost-effectiveness, making large-scale metagenomic projects more economically viable [3][4] Group 3: AI and Biological Insights - The EDEN model developed by Basecamp Research utilizes large-scale evolutionary metagenomic data to improve AI model performance, capturing biological signals that are often absent in curated reference genomes [2] - The collaboration aims to enable a new generation of AI systems capable of designing transformative medicines by integrating high-fidelity sequencing with advanced computational models [4][9]

Core Insights - The collaboration between PacBio and DNAstack aims to create the world's first global federated dataset of HiFi whole genome sequencing data, facilitating secure international research while maintaining data control [1][4][5] Group 1: Collaboration and Technology - The HiFi Solves Global Consortium includes nearly 30 clinical and research institutions across 15 countries, collectively connecting over 10,000 HiFi whole genome sequences, making it one of the largest federated datasets for rare disease research [3][8] - The platform allows researchers to query harmonized datasets without centralizing protected data, ensuring compliance with regional data privacy regulations [2][4] Group 2: Impact on Rare Disease Research - HiFi whole genome sequencing provides the accuracy needed to detect challenging variants, enhancing variant interpretation and accelerating discoveries for patients with rare diseases [4][5] - The federated model increases statistical power for rare disease studies, enabling insights that would be difficult to achieve with siloed datasets while preserving data sovereignty [4][5] Group 3: Recent Developments - In November 2025, consortium members published a study demonstrating that HiFi sequencing accurately identifies clinically relevant variants, achieving 100% detection of known variants and simplifying workflows [6]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [5][25] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [5][29] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [30][22] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [31][22] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by a growing installed base and consistent system utilization [25][6] - Instrument revenue rose 13% in Q4 2025 to $17.3 million, primarily due to increased shipments of Vega systems [26] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [29] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue grew 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [27][28] - The strong growth in EMEA was attributed to increased clinical adoption and higher shipments of Vega instruments [28] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock unique biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [9][52] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [33] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [34] Other Important Information - The company ended 2025 with approximately $280 million in cash and investments, down from $389.9 million at the end of 2024 [23][33] - The recent sale of short-read sequencing assets for approximately $48 million is expected to strengthen the balance sheet and extend the cash runway [24] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in EMEA, with many customers moving from pilot testing to broader clinical adoption [52] Question: What is the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining funding for critical programs [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51]

Core Insights - PacBio reported a revenue increase of 14% year-over-year for Q4 2025, reaching $44.6 million, and a total revenue of $160.0 million for FY 2025, up from $154.0 million in FY 2024 [2][11]. Financial Performance - Q4 2025 revenue was $44.6 million, compared to $39.2 million in Q4 2024, marking a 14% increase [2]. - Consumable revenue for Q4 2025 was $21.6 million, up from $18.8 million in Q4 2024, while instrument revenue decreased to $17.3 million from $15.3 million [2]. - Gross profit for Q4 2025 was $16.6 million, compared to $10.1 million in Q4 2024, with a non-GAAP gross margin of 40% in Q4 2025 versus 31% in Q4 2024 [3][6]. - GAAP operating expenses for Q4 2025 totaled $57.8 million, significantly lower than $163.1 million in Q4 2024 [4]. - The GAAP net loss for Q4 2025 was $40.4 million, compared to a net income of $2.4 million in Q4 2024, which included a $154.4 million gain on debt restructuring [4][8]. Annual Results - For FY 2025, GAAP gross profit was $45.8 million, up from $37.3 million in FY 2024, with a non-GAAP gross margin of 40% compared to 33% in FY 2024 [6]. - GAAP operating expenses for FY 2025 were $599.6 million, compared to $511.6 million in FY 2024, while non-GAAP operating expenses decreased to $229.9 million from $289.2 million [7]. - The GAAP net loss for FY 2025 was $546.4 million, compared to a loss of $309.9 million in FY 2024 [8]. Product and Market Developments - The company placed 21 Revio systems and 42 Vega systems in Q4 2025, with a total of 61 Revio and 140 Vega systems placed for the full year [2]. - The annualized Revio pull-through per system was approximately $242,000 in Q4 2025, slightly up from $240,000 in Q4 2024 [2]. - The company highlighted record consumables revenue and growth in the clinical market, positioning itself for future growth with the upcoming launch of the SPRQ-Nx system [11]. Balance Sheet and Cash Position - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $279.5 million, down from $389.9 million a year earlier [29].

Core Insights - PacBio has announced a collaboration with iHope to integrate its HiFi long-read whole-genome sequencing technology into iHope's global rare disease network, enhancing genomic insights for rare disease patients [1][2][3] Company Overview - PacBio is a leading provider of high-quality long-read sequencing technologies, focusing on resolving genetically complex problems across various research applications, including human germline sequencing and oncology [5] - iHope, a program of Genetic Alliance, operates the world's largest equitable rare-disease genomic testing network, supporting over 1,000 patients annually through 25 clinical sites in 14 countries [2][8] Collaboration Details - The integration of PacBio's HiFi long-read sequencing is expected to begin in early 2026, aiming to provide more comprehensive genomic insights and improve diagnostic clarity for rare disease patients [4] - This collaboration will enhance iHope's ability to explore challenging regions of the genome and additional classes of genetic variation, ultimately broadening opportunities for patients with unresolved findings [3][4] Impact on Patients - The partnership is designed to deliver advanced genomic tools to families historically lacking access, positively impacting patient lives across diverse populations [4][7] - By combining PacBio's sequencing technology with iHope's diagnostic approaches, the collaboration aims to support precision care and research into therapeutic strategies [3][4]

Core Viewpoint - PacBio has completed the sale of select intellectual property and assets related to its short-read DNA sequencing technology to Illumina, Inc., receiving $48.1 million in net cash proceeds from the transaction [1][2]. Group 1: Transaction Details - The transaction involved Illumina assuming certain liabilities and granting a non-exclusive license of specific intellectual property back to PacBio [2]. - The deal was finalized on January 30, 2026 [3]. Group 2: Strategic Focus - In response to challenging macroeconomic conditions, PacBio paused the development of its high-throughput short-read sequencing platform to concentrate on its long-read sequencing innovations [3]. - The sale strengthens PacBio's balance sheet and allows the company to focus on driving the adoption of its long-read sequencing platform, particularly the accelerated development of SPRQ-Nx chemistry [3]. Group 3: Company Overview - PacBio is a leading life science technology company that designs and manufactures advanced sequencing solutions for various research applications, including human germline sequencing, oncology, and infectious disease [4].

Financial Performance & Growth - Preliminary 2025 revenue is approximately $160 million[14] - The company's cash and investments balance as of December 31, 2025, is approximately $280 million[14] - Preliminary Q4 2025 revenue is approximately $44.6 million[14] - Consumables revenue is expected to be approximately $82 million in 2025[16] - Human genomics is fueling growth in consumables, with the human market reaching approximately $48.9 million in 2025[19] Instrument Placements & Technology - Total instrument placements in 2025 reached 210[14] - Revio placements in 2025 totaled 61, with a 20% shipment growth in clinical and commercial accounts[22] - Total Revio product line shipments since launch in 2023 are approximately $334 million[24] - Vega placements in 2025 are approximately 140, representing approximately 65% of new to PacBio customers[31, 34] - Vega product line shipments in 2025 are approximately $24 million[32] Market & Clinical Adoption - The total addressable market is approximately $9 billion in 2028, expected to grow approximately 7% annually[12] - Shipments to clinically focused customers grew over 40% in 2025[38]

Core Insights - PacBio reported preliminary unaudited revenue for Q4 2025 of $44.6 million, reflecting a 14% year-over-year growth, and full-year revenue of $160.0 million, representing a 4% increase compared to 2024 [1][2] Financial Performance - Q4 2025 revenue breakdown includes: - Instrument revenue of approximately $17.3 million, up from $15.3 million in Q4 2024 - Consumable revenue of approximately $21.6 million, an increase from $18.8 million in Q4 2024 - Service and other revenue of approximately $5.7 million, compared to $5.1 million in Q4 2024 [2] - Full-year 2025 revenue breakdown includes: - Instrument revenue of approximately $53.8 million, down from $65.8 million in 2024 - Consumable revenue of approximately $81.9 million, up from $70.3 million in 2024 - Service and other revenue of approximately $24.3 million, compared to $17.9 million in 2024 [2] Product Performance - The company placed 21 Revio systems and 42 Vega systems in Q4 2025, compared to 23 and 7 placements respectively in Q4 2024 - For the full year 2025, 61 Revio systems and 140 Vega systems were placed, down from 97 and 7 placements in 2024 [2] - The annualized Revio pull-through per system was approximately $242,000 in Q4 2025, slightly up from $240,000 in Q4 2024 [2] Strategic Outlook - The CEO highlighted strong momentum from increased sales of Revio and Vega systems, along with record consumables revenue, indicating traction in clinical sequencing applications - The company aims to reduce cash burn and strengthen its financial profile, with expectations for growth driven by real-world evidence and lower costs from the SPRQ-Nx technology in 2026 and beyond [2]

Financial Performance - Total revenue for Q3 2025 was $3844 million, a decrease of 4% year-over-year (Y/Y)[12, 54] - Consumable revenue reached $213 million, showing a 15% Y/Y increase and a 12% quarter-over-quarter (Q/Q) increase[12, 36] - Instrument revenue was $113 million, a decrease of 33% Y/Y and 20% Q/Q, attributed to lower Vega shipments, especially in Europe[12, 36] - Non-GAAP gross profit was $162 million with a gross margin of 42%, compared to $130 million and 33% in Q3 2024, respectively[38] - Non-GAAP operating expenses were $539 million, lower than the $624 million in Q3 2024[38] - Non-GAAP net loss was $368 million, an improvement from the $460 million loss in Q3 2024[38] - Cash and investments stood at $2987 million as of September 30, 2025[38, 60] - The company narrows its FY 2025 revenue guidance to $155-$160 million[39] Product and Technology Updates - Revio system shipments continue, with approximately 75% going to new customers[12] - Vega system shipments also persist, with about 60% going to new customers[12] - Sequel® II CNDx received Class III Medical Device Registration approval in China[16] - SPRQ-Nx chemistry is planned for launch in 2026, aiming for a cost of less than $300 per genome at scale[27] Clinical and Research Highlights - HiFi sequencing was selected for the National Institute on Aging's Long Life Family Study, involving up to 7800 whole genomes and epigenomes[24] - HiFi sequencing was selected for the Korean Pangenome Reference Project led by KCDC, targeting over 1000 Korean genomes[26]

Core Insights - PacBio has launched an enhanced suite of PureTarget products aimed at the high-throughput carrier screening market, consolidating multiple specialized assays into a single scalable solution for inherited disease screening [1][5] Group 1: Product Features - The updated PureTarget solutions utilize PacBio's HiFi sequencing technology to address challenging genes associated with inherited conditions, allowing for a more comprehensive carrier screening approach [1][3] - The new product line includes 24- and 96-sample kit formats, designed to meet various laboratory needs and streamline workflows [3][4] - The upgraded kits can process up to 100,000 samples annually on a single Revio system, making them suitable for large-scale screening initiatives [4] Group 2: Market Context - Recent research indicates that up to 71% of individuals carry at least one pathogenic variant, underscoring the increasing relevance of carrier screening in family planning [2] - The demand for carrier screening is growing across commercial labs, health systems, and government-funded programs globally, highlighting the need for efficient and comprehensive testing solutions [2][5] Group 3: Strategic Implications - PacBio's entry into the carrier screening market reflects a commitment to simplifying complex genomic testing and expanding access to comprehensive screening worldwide [5] - The consolidation of fragmented workflows into a single test is expected to enhance operational efficiency and clinical outcomes for laboratories [5]